Iterative Scopes

About

Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space.

Cambridge,Massachusetts,United States
101 - 250
http://www.iterativescopes.com

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $150M
Industries: Computer Vision,Health Care,Health Diagnostics,Medical
Founded date: Oct 1, 2017
Number Of Employee: 101 - 250
Operating Status: Active
Legal Name: Iterative Scopes, Inc

Iterative Scopes delivers tools for physicians and life sciences in colorectal cancer and inflammatory bowel disease space.

The company was founded in 2017 and is based in Cambridge, Massachusetts.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

11

$193.62M

Iterative Scopes has raised a total of $193.62M in funding over 2 rounds. Their latest funding was raised on Jan 19, 2022 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 19, 2022	Series B	$150M	7	Clearlake Capital Group Insight Partners	—	Detail
Aug 3, 2021	Series A	$30M	8	Obvious Ventures	—	Detail
Feb 22, 2021	Series Unknown	—	1	—	—	Detail
Dec 1, 2020	Seed	$2.02M	—	—	—	Detail
Sep 1, 2020	Seed	$4.50M	—	—	—	Detail

Investments

Number of Investments

Number of Lead Investments

1

0

Iterative Scopes has made 1 investments. Their most recent investment was on Jul 10, 2020, when RipeLocker raised $2M.

Date Company Name	Round	Money Raised	Industry	Lead Investor
Jul 10, 2020 RipeLocker	Series A	$2M	AgTech	—

Investors

Number of Lead Investors

Number of Investors

5

18

Iterative Scopes is funded by 18 investors. Clearlake Capital Group and Insight Partners are the most recent investors.

Investor Name	Lead Investor	Funding Round
Clearlake Capital Group	Yes	Series B
Insight Partners	Yes	Series B
MIT delta v	Yes	Non-Equity Assistant
Alumni Ventures	—	Series B
Breyer Capital	—	Series B
Eli Lilly	—	Series B
Johnson & Johnson Innovation – JJDC	—	Series B
Obvious Ventures	—	Series B
Lee Shapiro	—	Series A
Nat Turner	—	Series A